National and Kapodistrian University of Athens
Μελέτη της GSK-3β σε πρωτεϊνικό και μοριακό επίπεδο σε οικογενή και σποραδικά καρκινώματα μαστού
Abstract
dc:descriptionINTRODUCTION. Breast cancer represents the most common malignancy and cause of cancer -related deaths in female population Worldwide .Although we observe an increase of new-diagnosed cases the death percent is diminuished. This fact is due to new and extensive models of screening ,the new generation of mammography and new therapeutic approaches.This statistic data impones as to expand our researching horizons towards promising fields of reliable diagnostic, therapeutic and prognostic factors. AIM.The aim of this study was the investigation of: Ο σκοπός της παρούσης μελέτης είναι: 1) The expression pattern of protein kinase GSK-3β in primary invasive breast carcinomas(sporadic and familial) , 2) The existence of mutations in the exons 5 and 6(chr. 3q13.3)of the gene GSK-3β . The results will be correlated with the : α) classical clinicopathological parameters(age,menopausal status,tumor size,histological type,nuclear grade of malignancy, stage of disease,hormone receptors) b) overall survival(OS) and progression free survival(PFS) c) biological markers (ER, PR ,β-catenin, AKT, m-TOR). MATERIALS AND METHODSA)The material is consisted of 266 females with primary invasive breast cancer: a)154 sporadic cases, b)112 familial and c) 20 samples of mammary tissue negative to malignancy. The definition of the immunohistochemical expression and of the mutations of the gene GSK-3β will be held in slides of paraffin embedded tissue. B) We applied the three step imunohistochemical method avidin-biotin-hyperoxydase complex. The antibody we used is the rabbit polyclonal GSK-3β (H-76), in dilution 1:70. C) For the study of possible mutations of the gene GSK-3β,exons 5 and6 we used the method of QIAamp DNA Mini Kit/ PCR, with the respective primers,and electrophoresis in agar gel . The fact of bibliographic absence of this kind of mutations forced us to perform trials of acceptable credibility of the method(temperature,time and number of reaction cycles) and then followed the sequencing of PCR in the cases of our study. D) The results and the individual correlations were valuated with statistic methods ,Chi-square test for the biological markers, individual(log rank test) and multivariate( Cox”s hazard regression model) for the valutation of the survival(OS and PFS) . As level of for all the analysis is considered the p<0.05. It is used the SPSS, version 17.00 (SPSS Inc, Chicago ,IL).RESULTS GSK-3β was detected at the cytoplasm of the cancer cells in 57%(152/266),in the stromal fibroblasts in 28,7%(76/266) and in both populations(malignant and fibroblasts) in 27%(72/266).Neither cytoplasmic or stromal expression was associated with any of the classical clinicopathological parameters(lymphnode metastasis,menopausal status,tumor size,histological type,nuclear grade of malignancy, stage of disease,) or familial history.The cytoplasmic localization of the protein was positively associated with the expression of HER-2(p=0.045) and Akt ( p=0.039) ,and inversely with protein PTEN (p=0.011).The stromal expression of GSK-3β correlated positively with the expression of protein caspase-3 (p=0.020)and inversely with the expression of estrogen receptors (ER) (p=0.035),and of the immunohistochemical expression of Ki-67(p=0.015 ) and pAkt ( p=0.046). Neither cytoplasmic or stromal expression was found to to have any impact on overall survival(OS) and progression free survival(PFS) ,although in the subgroup of patients with HER-2 negative,was found to exert an unfavorable impact progression free survival(PFS) (p=0.021 .Even so over expression of GSK was observed, no activating mutations in the exons 5 and 6 of the gene GSK-3β kinas was found. This fact could be related to after- transduction modifications or inhibition of the natural inhibitors..CONCLUSIONS The role of protein kinas GSK-3β in the evolution of the cancer is not defined yet. Many studies support the oncogenic and others the antioncogenic activity.In breast cancer the absence of mutations ,a fact that is well documented to all neoplastic or not diseases ,do not allowed the targeted therapeutical approach at molecular level.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Vamvakaris, Ioannis
- Βαμβακάρης, Ιωάννης
Subjects
dc:subject × 7Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43785